Literature DB >> 18822469

Clinical manifestations of hyperuricemia and gout.

Brian F Mandell1.   

Abstract

Biologically significant hyperuricemia occurs when serum urate levels exceed urate solubility, ie, at approximately 6.8 mg/dL. At serum urate levels above this threshold, manifestations of chronic crystal deposition, including gouty arthritis, may occur, although asymptomatic hyperuricemia often persists for many years without progression. Intercritical asymptomatic periods follow the resolution of acute gout flares, but crystals remain in the joint during these intervals and further deposition may continue silently. Ultimately this may lead to persistent attacks, chronic pain, and, in some patients, joint damage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18822469     DOI: 10.3949/ccjm.75.suppl_5.s5

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  24 in total

Review 1.  Difficult-to-treat gouty arthritis: a disease warranting better management.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

Review 2.  Update on biology: uric acid and the activation of immune and inflammatory cells.

Authors:  Fabio Martinon
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

3.  Size matters: observations regarding the sonographic double contour sign in different joint sizes in acute gouty arthritis.

Authors:  C Löffler; H Sattler; U Löffler; B K Krämer; R Bergner
Journal:  Z Rheumatol       Date:  2018-11       Impact factor: 1.372

4.  Structure-based design of a hyperthermostable AgUricase for hyperuricemia and gout therapy.

Authors:  Yi Shi; Ting Wang; X Edward Zhou; Qiu-Feng Liu; Yi Jiang; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2019-06-28       Impact factor: 6.150

Review 5.  A novel enzymatic approach in the production of food with low purine content using Arxula adeninivorans endogenous and recombinant purine degradative enzymes.

Authors:  Dagmara A Jankowska; Anke Trautwein-Schult; Arno Cordes; Rüdiger Bode; Keith Baronian; Gotthard Kunze
Journal:  Bioengineered       Date:  2015-01-08       Impact factor: 3.269

6.  Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoporotic Fractures in Men (MrOS) study.

Authors:  Nancy E Lane; Neeta Parimi; Li-Yung Lui; Barton L Wise; Wei Yao; Yu-An Evan Lay; Peggy M Cawthon; Eric Orwoll
Journal:  J Bone Miner Res       Date:  2014-07       Impact factor: 6.741

Review 7.  Update on gout: new therapeutic strategies and options.

Authors:  Robert Terkeltaub
Journal:  Nat Rev Rheumatol       Date:  2010-01       Impact factor: 20.543

8.  Place of orthopedic surgery in gout.

Authors:  Recep Öztürk; İsmail Burak Atalay; Emin Kürşat Bulut; Galip Beltir; Selçuk Yılmaz; Bedii Şafak Güngör
Journal:  Eur J Rheumatol       Date:  2019-09-05

9.  Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study.

Authors:  Naomi Schlesinger; Marc De Meulemeester; Andrey Pikhlak; A Eftal Yücel; Dominik Richard; Valda Murphy; Udayasankar Arulmani; Peter Sallstig; Alexander So
Journal:  Arthritis Res Ther       Date:  2011-03-25       Impact factor: 5.156

10.  Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease.

Authors:  Klaus Stark; Wibke Reinhard; Martina Grassl; Jeanette Erdmann; Heribert Schunkert; Thomas Illig; Christian Hengstenberg
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.